Tagawa, S. T., Ramaswamy, K., Huang, A., Mardekian, J., Schultz, N. M., Wang, L., … George, D. J. (2022). Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis, 25(4), 800–801. https://doi.org/10.1038/s41391-021-00401-9

Tagawa, Scott T., Krishnan Ramaswamy, Ahong Huang, Jack Mardekian, Neil M. Schultz, Li Wang, Rickard Sandin, Stanislav Lechpammer, and Daniel J. George. “Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis 25, no. 4 (April 2022): 800–801. https://doi.org/10.1038/s41391-021-00401-9.

Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, et al. Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800–1.

Tagawa, Scott T., et al. “Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.” Prostate Cancer Prostatic Dis, vol. 25, no. 4, Apr. 2022, pp. 800–01. Pubmed, doi:10.1038/s41391-021-00401-9.

Tagawa ST, Ramaswamy K, Huang A, Mardekian J, Schultz NM, Wang L, Sandin R, Lechpammer S, George DJ. Correction to: Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate. Prostate Cancer Prostatic Dis. 2022 Apr;25(4):800–801.